[go: up one dir, main page]

WO2006061650A3 - Methods, products and uses involving platelets and/or the vasculature - Google Patents

Methods, products and uses involving platelets and/or the vasculature Download PDF

Info

Publication number
WO2006061650A3
WO2006061650A3 PCT/GB2005/004764 GB2005004764W WO2006061650A3 WO 2006061650 A3 WO2006061650 A3 WO 2006061650A3 GB 2005004764 W GB2005004764 W GB 2005004764W WO 2006061650 A3 WO2006061650 A3 WO 2006061650A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
agents
gpvi
vasculature
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2005/004764
Other languages
French (fr)
Other versions
WO2006061650A2 (en
Inventor
Goetz Muench
Andreas Bueltmann
Oliver Vimpany Arnold Boucher
Suresh Babubhai Chahwala
Meinrad Gawaz
Martin Ungerer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trigen GmbH
Trigen Ltd
Original Assignee
Trigen GmbH
Trigen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/009,106 external-priority patent/US7531178B2/en
Application filed by Trigen GmbH, Trigen Ltd filed Critical Trigen GmbH
Priority to US11/792,857 priority Critical patent/US20090130021A1/en
Priority to EP05849048A priority patent/EP1824979A2/en
Publication of WO2006061650A2 publication Critical patent/WO2006061650A2/en
Publication of WO2006061650A3 publication Critical patent/WO2006061650A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure relates to agents which interfere with the binding of GPVI to various components. Agents which interfere with GPVI Interaction with one or both of fibronectin and vironectin or sequences thereof are also disclosed. Methods of treating disorders or diseases which involve pathological, dysfunctional or non-pathological interaction of GPVI with fibronectin and/or vitronectin are included in the present disclosure. The invention also relates to uses of agents for the prevention or treatment of disorders arising from blood platelet adhesion and aggregation.
PCT/GB2005/004764 2002-06-07 2005-12-12 Methods, products and uses involving platelets and/or the vasculature Ceased WO2006061650A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/792,857 US20090130021A1 (en) 2002-06-07 2005-12-12 Methods, products and uses involving platelets and/or the vasculature
EP05849048A EP1824979A2 (en) 2004-12-10 2005-12-12 Methods, products and uses involving platelets and/or the vasculature

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/009,106 2004-12-10
US11/009,106 US7531178B2 (en) 2002-06-07 2004-12-10 Immunoadhesin comprising a glycoprotein VI domain
EP05256993 2005-11-11
EP05256993.6 2005-11-11

Publications (2)

Publication Number Publication Date
WO2006061650A2 WO2006061650A2 (en) 2006-06-15
WO2006061650A3 true WO2006061650A3 (en) 2006-08-17

Family

ID=36337522

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/004764 Ceased WO2006061650A2 (en) 2002-06-07 2005-12-12 Methods, products and uses involving platelets and/or the vasculature

Country Status (2)

Country Link
EP (1) EP1824979A2 (en)
WO (1) WO2006061650A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007091719A1 (en) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. Concomitant anti-gpvi antibody therapy and novel medicinal use thereof
JPWO2007116779A1 (en) 2006-03-31 2009-08-20 持田製薬株式会社 Novel platelet activation marker and measuring method thereof
CN107011445B (en) 2007-06-01 2021-06-29 马里兰大学巴尔的摩分校 Immunoglobulin constant region Fc receptor binding agents
CN102026659A (en) * 2008-04-22 2011-04-20 Csl百灵有限公司 Method for preventing and treating cancer by inhibiting GPVI
WO2010141771A1 (en) * 2009-06-03 2010-12-09 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein vi
US8889645B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
US8889646B2 (en) 2009-06-03 2014-11-18 Regado Biosciences, Inc. Nucleic acid modulators of glycoprotein VI
WO2011013792A1 (en) * 2009-07-30 2011-02-03 富士フイルム株式会社 Kidney imaging agent comprising genetically modified gelatin
EP2397495A1 (en) * 2010-06-21 2011-12-21 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
AU2010331807B2 (en) * 2009-12-18 2016-08-04 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2336188A1 (en) * 2009-12-18 2011-06-22 Sanofi-Aventis Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP3543257A1 (en) 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
US10468565B2 (en) 2012-06-11 2019-11-05 Cree, Inc. LED package with multiple element light source and encapsulant having curved and/or planar surfaces
EP2885320A4 (en) 2012-08-20 2016-04-06 Gliknik Inc Molecules with antigen binding and polyvalent fc gamma receptor binding activity
KR102649702B1 (en) 2015-07-24 2024-03-21 글리크닉 인코포레이티드 Fusion proteins of human protein fragments to generate regularly polymorphized immunoglobulin FC compositions with improved complement binding
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
AU2017371179B2 (en) 2016-12-09 2022-07-14 Gliknik Inc. Manufacturing optimization of GL-2045, a multimerizing stradomer
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
CN108918564B (en) * 2018-08-09 2021-02-02 陕西延长石油(集团)有限责任公司研究院 Analysis method suitable for shale mineral component quantification
CN111134760B (en) * 2020-02-18 2024-09-13 绵竹市人民医院 A device for pressing and stopping bleeding in minimally invasive surgery

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080968A1 (en) * 2001-04-09 2002-10-17 Millennium Pharmaceuticals, Inc. Glycoprotein vi and uses thereof
WO2003008454A2 (en) * 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
WO2003104282A2 (en) * 2002-06-07 2003-12-18 Procorde Gmbh Immunoadhesin comprising a glycoprotein vi domain
WO2005007674A2 (en) * 2003-07-11 2005-01-27 Molecular Innovations Anti-human vitronectin antibody and methods for making the same
WO2005054294A2 (en) * 2003-12-03 2005-06-16 Trigen Gmbh Inhibitors of glycoprotein vi based on monoclonal antibody hgp 5c4

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080968A1 (en) * 2001-04-09 2002-10-17 Millennium Pharmaceuticals, Inc. Glycoprotein vi and uses thereof
WO2003008454A2 (en) * 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
WO2003104282A2 (en) * 2002-06-07 2003-12-18 Procorde Gmbh Immunoadhesin comprising a glycoprotein vi domain
WO2005007674A2 (en) * 2003-07-11 2005-01-27 Molecular Innovations Anti-human vitronectin antibody and methods for making the same
WO2005054294A2 (en) * 2003-12-03 2005-06-16 Trigen Gmbh Inhibitors of glycoprotein vi based on monoclonal antibody hgp 5c4

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CIERNIEWSKI C ET AL: "Anti-(Arg-Gly-Asp-Ser) antibody and its interaction with fibronectin, fibrinogen and platelets", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 177, no. 1, October 1988 (1988-10-01), pages 109 - 115, XP002099824, ISSN: 0014-2956 *
GRÜNER S ET AL: "Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 105, no. 4, 15 February 2005 (2005-02-15), pages 1492 - 1499, XP002375721, ISSN: 0006-4971 *
SCHULZ CHRISTIAN ET AL: "Glycoprotein VI mediates platelet adhesion to endothelial cells in vivo", CIRCULATION, vol. 112, no. 17, Suppl. S, October 2005 (2005-10-01), & 78TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; DALLAS, TX, USA; NOVEMBER 13 -16, 2005, pages U93, XP009067061, ISSN: 0009-7322 *
SMETHURST PETER A ET AL: "Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody.", BLOOD, vol. 103, no. 3, 1 February 2004 (2004-02-01), pages 903 - 911, XP002383117, ISSN: 0006-4971 *
WU YA-PING ET AL: "Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin.", BLOOD. 15 AUG 2004, vol. 104, no. 4, 15 August 2004 (2004-08-15), pages 1034 - 1041, XP002383118, ISSN: 0006-4971 *
YANG C H ET AL: "Inhibition of RPE cell-mediated matrix adhesion and collagen gel contraction by crovidisin, a collagen-binding snake venom protein.", CURRENT EYE RESEARCH. NOV 1997, vol. 16, no. 11, November 1997 (1997-11-01), pages 1119 - 1126, XP009067064, ISSN: 0271-3683 *

Also Published As

Publication number Publication date
WO2006061650A2 (en) 2006-06-15
EP1824979A2 (en) 2007-08-29

Similar Documents

Publication Publication Date Title
WO2006061650A3 (en) Methods, products and uses involving platelets and/or the vasculature
CA2726087A1 (en) Dual variable domain immunoglobulins and uses thereof
WO2006023544A3 (en) Therapeutic uses of inhibitors of rtp801
WO2007117381A3 (en) 2 -aminopyridine analogs as glucokinase activators
WO2008157733A3 (en) Fibrin gel for controlled release of pdgf and uses thereof
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
WO2007005879A3 (en) Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
EP3050876A3 (en) Kinase modulators
WO2009149185A3 (en) Dual variable domain immunoglobulins and uses thereof
HK1209021A1 (en) Nanotherapeutics for drug targeting
WO2007040650A3 (en) Apoptosis promoters
WO2006099111A3 (en) Aneurysm treatment devices
WO2007053189A3 (en) Compositions and methods for altering immune function
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
ATE473636T1 (en) FOODS CONTAINING PROBIOTIC AND ISOLATED BETA-GLUCAN AND METHOD OF USE THEREOF
WO2018042438A3 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
WO2009021708A3 (en) Ivig modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease
WO2008029169A3 (en) Method of treating respiratory disorders
WO2008118718A3 (en) 2-aminopyridine analogs as glucokinase activators
WO2007084684A3 (en) Therapeutic uses of inhibitors of rtp801
WO2008003943A3 (en) Inhibition of alpha-synuclein aggregation
WO2006002262A3 (en) Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2005116088A3 (en) Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells
WO2014197816A8 (en) Stimulus responsive nanocomplexes and methods of use thereof
TW200606177A (en) Glycoprotein VI antibodies and methods thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005849048

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005849048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11792857

Country of ref document: US